Unichem Laboratories Limited has announced the successful completion of Phase I of its Active Pharmaceutical Ingredient (API) plant expansion at Pithampur. The company informed the stock exchanges that this expansion will significantly enhance its production capabilities and ensure greater self-reliance in API manufacturing.
According to the regulatory filing, the company has increased its capacity by 210 KL, adding to its existing capacity of 259.5 KL. Currently, the utilization rate of the facility stands at approximately 70%. The total investment for this expansion amounts to Rs 200 crore, funded through a combination of internal accruals and bank borrowings.
Unichem Laboratories emphasized that the expanded API production will primarily serve the company’s internal requirements, ensuring a stable supply chain for its pharmaceutical formulations. The move aligns with the company’s long-term strategy of strengthening its API production capabilities and reducing dependency on external sources.
The Pithampur expansion marks a crucial step for Unichem Laboratories in its growth trajectory, positioning it for greater efficiency and self-sufficiency in API manufacturing. Investors and stakeholders are expected to closely monitor further developments as the company progresses with its expansion plans.
